The UC Davis MIND Institute condemns the ongoing racism and violence targeting people of color. We are committed to fulfilling our mission to help all families affected by neurodevelopmental challenges and to promote equal access to high quality health care and education for all members of our community.
Mindfulness group now enrolling parents
Get Mindful, an online support and self-care group for parents of children with neurodevelopmental conditions, is now enrolling for a session that runs from February to April.
Loss of function may be onset of FXTAS
UC Davis Health research finds that executive function challenges may signal the onset of fragile X-associated tremor-ataxia syndrome (FXTAS) in some FMR1 premutation carriers.
Join our Research Community
Participate in our studies to help Researchers better understand neurodevelopmental disabilities.
Science MINDS: Stephen Hinshaw
Host Andrew Dakopolos talks with Professor Stephen Hinshaw about how his father’s struggle with mental illness inspired Hinshaw’s interest in psychology and his efforts to fight the stigma surrounding mental health. Hinshaw also shares how his career evolved and led to an interest in developmental disabilities, specifically in ADHD in girls and women. He started the Berkeley Girls with ADHD Longitudinal Study, which has been running for more than 25 years. Hinshaw is a distinguished professor of psychology at UC Berkeley and a professor of psychiatry and behavioral sciences at UC San Francisco.
MIND Institute Instagram
Built by Families for Families
The MIND Institute is an interdisciplinary, collaborative research, clinical, and educational center committed to deepening our scientific understanding of the challenges associated with autism and other neurodevelopmental conditions.
The vision of the MIND Institute is to develop more personalized, equitable, and scientifically validated systems of support and interventions that help neurodivergent individuals to live their best lives.
The MIND Institute is especially known for research and clinical therapies developed for: